88 related articles for article (PubMed ID: 12974393)
1. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Hantke B; Harbeck N; Schmalfeldt B; Claes I; Hiller O; Luther MO; Welk A; Kuhn W; Schmitt M; Tschesche H; Muehlenweg B
Biol Chem; 2003 Aug; 384(8):1247-51. PubMed ID: 12974393
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
4. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
5. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
6. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis.
Laudanski P; Szamatowicz J; Ramel P
Gynecol Endocrinol; 2005 Aug; 21(2):106-10. PubMed ID: 16109597
[TBL] [Abstract][Full Text] [Related]
8. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.
Zucker S; Lysik RM; Zarrabi MH; Moll U
Cancer Res; 1993 Jan; 53(1):140-6. PubMed ID: 8416738
[TBL] [Abstract][Full Text] [Related]
9. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer.
Demeter A; Sziller I; Csapo Z; Olah J; Keszler G; Jeney A; Papp Z; Staub M
Anticancer Res; 2005; 25(4):2885-9. PubMed ID: 16080542
[TBL] [Abstract][Full Text] [Related]
10. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
12. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
14. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
15. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
16. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent.
Masunaga Y; Hirahara I; Shimano Y; Kurosu M; Iimura O; Miyata Y; Amemiya M; Homma S; Kusano E; Asano Y
Clin Exp Nephrol; 2005 Mar; 9(1):85-9. PubMed ID: 15830280
[TBL] [Abstract][Full Text] [Related]
17. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer.
Noh S; Jung JJ; Jung M; Kim TS; Park CH; Lim SJ; Jeung HC; Cheol H; Chung HC; Rha SY
Hepatogastroenterology; 2011; 58(112):2015-9. PubMed ID: 22024074
[TBL] [Abstract][Full Text] [Related]
18. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
19. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer.
Périgny M; Bairati I; Harvey I; Beauchemin M; Harel F; Plante M; Têtu B
Am J Clin Pathol; 2008 Feb; 129(2):226-31. PubMed ID: 18208802
[TBL] [Abstract][Full Text] [Related]
20. [Interactions of ovarian carcinoma cells and human peritoneal mesothelial cells involved in matrix metalloproteinases expressions of ovarian carcinoma cells].
Zhang JJ; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2006 Mar; 41(3):194-7. PubMed ID: 16640888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
